August 10, 2017
John Snow Focuses Practice on Hatch-Waxman Work

Polsinelli, an Am Law 100 firm, announced today that intellectual property litigator John Snow joined its Chicago office as a shareholder.

Snow concentrates his practice in the areas of pharmaceutical, biochemical, chemical litigation and opinions, with an emphasis on patent matters and issues related to the Hatch-Waxman Act. He has served as trial counsel for various patent litigations in U.S. federal courts and has experience counseling biosimilar manufacturers and formulating strategies regarding the BPCIA.

Snow prepares and prosecutes U.S. and international patents in the chemical arts, and consults and renders opinions on patentability, infringement, validity, and enforceability.

“John is a great addition to our team,” said Gary E. Hood, who leads the firm’s Hatch-Waxman litigation division. “We see a growing need for this expertise from our clients in the pharmaceutical and biotech industries and John’s demonstrated the ability to partner with them in developing strategies suited to their unique business goals.”

Polsinelli has one of the largest Intellectual Property practices in the nation. The firm’s Hatch-Waxman team has deep experience leading Abbreviated New Drug Application (ANDA) cases and represents some of the world’s largest, best-known, and most influential generic, brand, and specialty pharmaceutical companies, litigating everything from blockbuster products, to smaller market and specialty pharmaceuticals, in both first-to-file and later filer cases.

“It’s exciting to join a practice with such an outstanding group of attorneys and such a sharp focus on this work. I am eager to join a practice group with the breadth and depth of Polsinelli’s Intellectual Property team as well as joining a firm that takes a business-minded approach to all areas of law,” Snow said.

Snow is a graduate of University of Michigan Law School.